TGTX

TG Therapeutics Inc.

Price

$51.69

return (12m)

85.14%

p/e

15.67

p/bv

11.45

DIVIDEND YIELD

0.00%

TGTX price

TG Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment TGTX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-4.74%

3 months

31.73%

1 year

85.14%

2 years

109.19%

5 years

97.52%

10 years

740.49%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals TGTX

Valuation

P/E

15.67

Sector -4.38

Industry -4.38

P/BV

11.45

Sector 2.02

Industry 2.02

P/Revenue (PSR)

8.65

Sector -4.40

Industry -4.40

EV/EBITDA

264.36

Sector -263.09

Industry -263.09

EV/EBIT

265.25

Sector -702.90

Industry -702.90

P/EBITDA

49.63

Sector -4.39

Industry -4.39

P/EBIT

49.74

Sector -4.73

Industry -4.73

P/Total Assets

4.22

Sector 1.49

Industry 1.49

P/Net Current Assets

62.81

Sector -11.70

Industry -11.70

P/Working Capital

7.89

Sector -3.19

Industry -3.19

EPS

3.11

Sector -2.14

Industry -2.14

BVPS

4.25

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

82.37%

Sector 36.74%

Industry 36.74%

EBITDA Margin

11.19%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

11.16%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

17.05%

Sector -38.22%

Industry -38.22%

Net Profit Margins

55.22%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.15

Sector 0.03

Industry 0.03

Profitability

ROE

73.08%

Sector -65.14%

Industry -65.14%

ROA

26.93%

Sector -65.53%

Industry -65.53%

ROIC

7.58%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

4.27

Sector 2.90

Industry 2.90

Net Debt / EBITDA

7.18

Sector -6.07

Industry -6.07

Net Debt / EBIT

7.20

Sector -8.26

Industry -8.26

Net Debt / Equity

0.32

Sector -1.07

Industry -1.07

Gross Debt / Equity

1.23

Sector -0.05

Industry -0.05

Equity/Assets

0.37

Sector 0.41

Industry 0.41

Liabilities/Assets

0.63

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

160.38%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF TG Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$51.69

Fair Value

$17.25

Upside Return potential.

-66.64%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals TGTX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
TGTX TG Therapeutics Inc.	$51.69	86.40%	0.00%	15.67	11.45	73.08%	55.22%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

TGTX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT TG Therapeutics

TG Therapeutics Inc.

Average Investor10 user rating

4.0 (4 people)

United States

33 years

Founded: 1993

1995

Time since IPO - 31 years

272

Employees

TG Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $6.92 billion, with shareholders equity totaling $604.08 million.

The company employs approximately 272 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, TG Therapeutics Inc. reported $799.54 million in revenue, generating net income of $441.49 million.

Key financial metrics include a P/E ratio of 15.67, a price-to-book (P/B) ratio of 11.45, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker TGTX.

Market cap

$6.92 billion

Net worth

$604.08 million

$604,080,000.00

Assets

$1.64 billion

$1,639,630,000.00

Total Shares Outstanding

142.00 million

142,000,000

Average Daily Trading Volume

$2.57 million

$2,573,358.20

Sector

Health Care

Industry

Biotechnology

TGTX

TGTX revenue and profits

Financial Results TGTX

DRAG THE FRAME TO SEE MORE DATA

TGTX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of TG Therapeutics (TGTX) today?

A cotação de TG Therapeutics (TGTX) hoje está em US$ 51.69, com uma variação de 85.14% em relação ao último ano. A cotação de TG Therapeutics (TGTX) iniciou o ano negociando na casa dos US$ 29.81 e hoje está em US$ 51.69. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de TG Therapeutics (TGTX) e dados de ações do Ibovespa e mercados internacionais.

Quando TG Therapeutics (TGTX) paga dividendos?

TG Therapeutics (TGTX) não distribuiu dividendos no último ano.

Is TG Therapeutics (TGTX) a good investment?

Atualmente, TG Therapeutics (TGTX) está cotada a US$ 51.69, com um P/L de 15.67, representando um desvio de 7,941% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 85.14 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 85.14%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy TG Therapeutics (TGTX) stock?

Investir em ações de TG Therapeutics (TGTX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of TG Therapeutics (TGTX) yield today?

A rentabilidade de TG Therapeutics (TGTX) foi de -4.74% no último mês, 85.14% no último ano e 97.52% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de TG Therapeutics (TGTX) hoje, o investimento total seria de US$ 5,169.00, com base na cotação atual de US$ 51.69.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 9,569.89
Em 5 anos: US$ 10,209.81
Em 10 anos: US$ 43,444.93

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

TGTX

TG Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment TGTX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING TGTX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT TG Therapeutics

TG Therapeutics Inc.

United States

33 years

1995

272

PROFIT X PRICE TGTX

Financial Results TGTX

TGTX cash flow

Asset, Revenue and Profit Growth - TGTX

TGTX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions